• Home
  • Overview
  • Technology
  • Market
  • Investors
    • Investor Login

AngioCure’s intellectual properties safeguard the company’s development of a new class of semi-compliant Smart Balloon Catheters; its proprietary physiologic metric and biofeedback technology system, PhysioSense™; its new class of Plug-N-Play Surgical Camera, AngioCam™; and its proprietary extravasated drug delivery platform, NanoVas.

These valuable assets afford the company a significant, next-generation advantage in the commercialization of sophisticated, physiologically intelligent devices. AngioCure’s technologies empower surgeons with an entirely new tool belt of devices that advance physicians’ intra-operative skills along with their intuitive command of vessel integrity to help them deliver safe, reprodicible results across the broad spectrum of diverse and challenging patient populations.  

FDA REGULATORY DISCLOSURE: AngioCure is an emerging technology company.These products are investigational medical devices that have not been approved or cleared for use in the United States.
A Sanovas Company
Back to Top